In a landmark transaction for the medical technology sector, private equity giants Blackstone and TPG have finalized their acquisition of Hologic, Inc., taking the women's health and diagnostics company private in a deal valued at approximately $17.3 billion. The transaction closed on April 7, 2026, marking the end of Hologic's tenure as a publicly traded entity.
Leadership Transition and Shareholder Payout
Effective immediately, José Almeida has assumed the role of Chief Executive Officer, replacing Steve MacMillan who has retired. Almeida brings extensive medtech experience, having previously led Baxter International from 2016 through early 2025 and serving as chairman and CEO of Covidien prior to its acquisition by Medtronic in 2015. In a statement, Almeida described his move to Hologic as a "pivotal moment" for the company.
Former Hologic shareholders will receive $76 per share in cash, plus a non-tradable contingent value right (CVR) that could provide up to an additional $3 per share. This potential earnout is contingent upon the company's global Breast Health revenue meeting specific, undisclosed targets during fiscal years 2026 and 2027. The total consideration represents a significant premium and concludes MacMillan's tenure, during which the company reported a 65% increase in revenue, 184% growth in non-GAAP earnings per share, and a 241% appreciation in share price over more than twelve years.
Delisting and Market Exit
Trading in Hologic shares was suspended on Nasdaq ahead of the April 7 closing. The company has formally requested delisting and will be removed from the S&P 500 index before the market opens on Thursday. Hologic also intends to file a Form 15 with the Securities and Exchange Commission, which will terminate its regular public reporting obligations. This move effectively removes a prominent medical device player from public markets, a transaction Reuters previously noted as one of the largest in the sector in nearly two decades.
Concurrent with the deal's closure, Hologic paid off its existing credit agreement and redeemed $400 million in notes due 2028 along with $950 million in notes due 2029. All pre-deal directors have resigned, with Almeida joining the board as part of the leadership transition.
Strategic Rationale for Going Private
Merger documents reveal the board's reasoning for approving the buyout. Directors cited Hologic's strong balance sheet—the company ended its most recent quarter with $2.17 billion in cash and equivalents—contrasted with lagging performance in the broader medtech and life sciences sector. The board expressed concern that public market investors' focus on short-term results could undermine longer-term investments in innovation and strategic acquisitions.
The company maintains considerable scale, reporting $1.05 billion in revenue for the first quarter of fiscal 2026, a 2.5% year-over-year increase. Its Breast Health segment grew 1.8% during the period. Hologic competes in diagnostics and imaging against major players including Roche Diagnostics, Abbott Laboratories, and GE HealthCare.
Challenges and Outlook
The path forward under private ownership includes notable challenges. The additional $3 per share CVR payout depends on Breast Health revenue targets that the company has not yet achieved. Hologic's fiscal 2025 filing showed a 9.1% decline in Breast Health product revenue, attributed to lagging mammography-system sales and extended sales cycles. The company also began fiscal 2026 facing $15.3 million in quarterly tariff costs.
Private equity partners expressed confidence in the company's trajectory. Blackstone's Ram Jagannath highlighted Hologic's "proven track record" in women's health, while TPG's Alex Albert noted his firm had "long admired" the company. The closing statement confirmed that sovereign wealth funds ADIA and GIC have taken minority stakes alongside the lead buyers.
The acquisition represents a significant bet on the future of women's healthcare and diagnostic technology outside the scrutiny of quarterly earnings reports. With strengthened balance sheets and freedom from public market pressures, Hologic's new owners are positioned to pursue longer-term strategic initiatives in a competitive global healthcare landscape.
